Lv21
110 积分 2023-12-04 加入
中国老年多发性骨髓瘤全程管理专家共识（2024年版）
6小时前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
24天前
已完结
Genomic complexity of multiple myeloma and its clinical implications
24天前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
High-risk Multiple Myeloma: Definition and Management
1个月前
已完结
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
1个月前
已完结
Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
2个月前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
3个月前
已完结
On an enhanced rank‐preserving structural failure time model to handle treatment switch, crossover, and dropout
5个月前
已完结
皖公网安备34019202002308
